NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

Nvidia, AbbVie, Vertex Pharmaceuticals And An Oil Giant: CNBC's 'Final Trades'

Published 17/06/2024, 13:47
© Reuters Nvidia, AbbVie, Vertex Pharmaceuticals And An Oil Giant: CNBC\'s \'Final Trades\'
VRTX
-
NVDA
-
COP
-
ABBV
-

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

On CNBC's “Halftime Report Final Trades,” Bryn Talkington of Requisite Capital Management named NVIDIA Corporation (NASDAQ:NVDA) as her final trade.

NVIDIA recently announced a 10-for-1 stock split. The semiconductor giant revealed this decision during its recent quarterly earnings report. The split-adjusted trading commenced on Monday, June 10.

Jim Lebenthal of Cerity Partners picked Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), which is a biopharmaceutical company.

On Friday, Vertex revealed positive long-term data on CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress.

Don't forget to check out our premarket coverage here

Kevin Simpson of Capital Wealth Planning named ConocoPhillips (NYSE:COP), saying the acquisition of Marathon Oil Corporation (NYSE:MRO) will be aggregate over time.

On Friday, BofA Securities analyst Kalei Akamine reinstated ConocoPhillips with a Buy rating and announced a price target of $147.

Rob Sechan of NewEdge Wealth said AbbVie Inc. (NYSE:ABBV) has an attractive valuation, wonderful pipeline and a great yield.

On June 6, AbbVie released topline results from the Phase 2 PICCOLO trial evaluating investigational mirvetuximab soravtansine (Elahere) monotherapy in heavily pre-treated patients with folate receptor-alpha (FRα) positive, platinum-sensitive ovarian cancer (PSOC). The study met its primary endpoint with an objective response rate (ORR) of 51.9%.

Price Action:

  • Nvidia shares gained 1.8% to close at $131.88 during Friday's session.
  • Vertex Pharmaceuticals shares rose 0.4% to close at $480.73 on Friday.
  • ConocoPhillips shares fell 1.4% to settle at $109.39 during Friday's session.
  • AbbVie gained 1.2% to close at $168.59 on Friday.
Check This Out: Wall Street’s Most Accurate Analysts Weigh In On 3 Tech Stocks With Over 3% Dividend Yields

Image generated using artificial intelligence via Midjourney.

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.